跳至主導覽
跳至搜尋
跳過主要內容
國立成功大學 首頁
English
中文
在 國立成功大學 搜尋內容
首頁
概要
研究單位
研究成果
專案
學生論文
設備
獎項
活動
查看斯高帕斯 (Scopus) 概要
林 景翰
Doctor
內科部
電子郵件
cyclops0113
yahoo.com
tw
h-index
296
引文
10
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2016
2026
每年研究成果
概覽
指紋
網路
研究成果
(20)
類似的個人檔案
(6)
指紋
查看啟用 Ching-Han Lin 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
61%
Insulin Resistance
45%
Non Insulin Dependent Diabetes Mellitus
40%
Carbamazepine
40%
Liver Dysfunction
40%
Levodopa-Induced Dyskinesia
40%
Helicobacter pylori
40%
Hedgehog
40%
Spontaneously Hypertensive Rat
40%
Infection
40%
Helicobacter Infection
40%
Hyperthyroidism
40%
Adenosine Triphosphate Sensitive Potassium Channel
40%
Fatty Liver
40%
Glucagon Like Peptide 1 Receptor Agonist
40%
Evodiamine
40%
Fenretinide
40%
Peroxisome Proliferator Activated Receptor Gamma
40%
Hemoglobin A1c
37%
Alanine Aminotransferase
34%
Diseases
30%
Glucagon-Like Peptide-1
24%
C Reactive Protein
20%
High Density Lipoprotein Cholesterol
20%
Nonalcoholic Fatty Liver
20%
Triacylglycerol
20%
Lipopolysaccharide
18%
Urea Breath Test
18%
Peroxisome Proliferator Activated Receptor
14%
Glucotoxicity
13%
Phosphoenolpyruvate Carboxykinase (GTP)
13%
Mild Hepatic Impairment
13%
Persistent Hyperinsulinemic Hypoglycemia of Infancy
11%
Sulfonylurea Receptor 1
11%
Oral Antidiabetic Agent
9%
Retrospective Study
8%
Liraglutide
8%
Clinical Study
8%
Dulaglutide
8%
Antidiabetic Agent
8%
Cytokine
7%
Inflammation
7%
Peroxisome Proliferator Activated Receptor Antagonist
7%
Recombinant Protein
6%
Liothyronine
6%
Graves Disease
6%
Channel Opener
6%
Hepatocyte Nuclear Factor 1
6%
Aspartate Aminotransferase
6%
Medicine and Dentistry
Diabetes
100%
Glycemic Control
81%
Patient with Diabetes
68%
Hemoglobin A1c
51%
Glycemic
45%
Patient with Type 2 Diabetes
40%
Helicobacter Infection
40%
Growth Differentiation Factor 15
40%
Diabetes Mellitus
40%
Infection
40%
Taste Bud
40%
Sucralose
40%
Hyperglycemia
40%
Placebo
40%
Helicobacter pylori
40%
Maturity Onset Diabetes of the Young
40%
Aldosterone-to-Renin Ratio
40%
Impaired Glucose Tolerance
40%
Metabolic Syndrome
40%
Oral Antidiabetic Agent
22%
Low Density Lipoprotein Cholesterol
19%
Urea Breath Test
18%
Glucose Tolerance
17%
Impaired Fasting Glucose
17%
Cardiovascular System
16%
Biological Marker
14%
Complementary Therapy
13%
Statin
13%
Health Outcomes
13%
Dyslipidemia
13%
Cancer
11%
Enzyme Linked Immunosorbent Assay
8%
Multiple Linear Regression Analysis
6%
High Density Lipoprotein Cholesterol
5%
Linear Regression Analysis
5%
Triacylglycerol
5%
Embryo Development
5%
Early Diagnosis
5%
C Reactive Protein
5%
Body Mass Index
5%
Diastolic Blood Pressure
5%
Prevalence
5%
Systolic Blood Pressure
5%
Keyphrases
Pre-diabetes (pre-DM)
81%
Hedgehog Proteins
81%
Impaired Fasting Glucose
48%
Growth Differentiation factor-15 (GDF-15)
40%
Collaborative Consensus
40%
Anti-hepatocellular Carcinoma Activity
40%
Type 2 Diabetes Mellitus (T2DM)
40%
Secretogranin III
40%
Levodopa-induced Dyskinesia
40%
Hepatic Dysfunction
40%
Non-obese
40%
Sucralose
40%
Taste Receptors
40%
Golgi Retention
40%
Primary Aldosteronism
40%
Hepassocin
40%
Hyperthyroidism
40%
Protein Level
40%
Obese Subjects
40%
Impaired Glucose Tolerance
38%
New-onset Diabetes
32%
Normal Glucose Tolerance
29%
Plasma Renin Activity
24%
Hepa1-6
13%
Mean Amplitude of Glycemic Excursions
13%
Diabetes
13%
Multiple Linear Regression Analysis
10%
Multifaceted Factors
10%
Abnormal Involuntary Movements
10%
High Growth
9%
Fasting Plasma Glucose
9%
Protein Concentration
9%
HepG2 Cells
8%
Direct Renin Concentration
8%
Phosphoenolpyruvate Carboxylase
8%
Hepatic Protective Effect
7%
Metabolic Disease
7%
First-time-in-human
6%
KATP Channel Opener
6%
Remote Infection
6%
Hyperglycemic Mice
6%
Real-world Evidence Study
5%
Metabolic Dysregulation
5%
Liver Disease Models
5%
